![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
ELC GROUP, one of the fastest-growing providers of regulatory affairs consulting services, today announced that John Warren, a former Expert Medical Assessor for the UK Medicines Healthcare products Regulatory Agency (MHRA) has joined the ELC GROUP Advisory Board.
John Warren is a world renowned clinical scientist holding triple specialist accreditation in the UK in General Medicine, Clinical Pharmacology and Cardiology. He is the author of over 100 publications in international journals on the physiology and pharmacology of the autonomic system and a book on the Endothelium.
John was a member of the European Scientific Advice Working Party from 2003 to 2010 and the European Pharmacokinetic Subgroup of the Efficacy Working Party from 2007 to 2008. He contributed to the EU Notes for Guidance on Asthma, COPD, ARDS and Bioequivalence. Previously he was a Senior Lecturer and Honorary Consultant at the National Heart & Lung Institute, London. He was also a Member of the Editorial Board of Clinical Pharmacology & Therapeutics and Microvascular Research and is currently Executive Editor for the British Journal of Clinical Pharmacology and member of the Joint Speciality Committee for Clinical Pharmacology of the Royal College of Physicians of London.
Speaking about the appointment, ELC GROUP CEO Marco Rubinstein said: “We are honoured to have an expert of John’s calibre join our advisory board and bring his exceptional knowledge and experience to ELC GROUP.”
ELC Group’s Business Development Manager Akhil Jain added: “We are very pleased to welcome John to ELC GROUP’s already exceptional Advisory Board. His academic contributions and vast experience in Regulatory Affairs make him a valuable new addition to our team.”
Commenting on his appointment, John Warren said: “ELC GROUP is a rapidly growing leading industry expert in global regulatory affairs consulting. I look forward to contributing to the continued strategic success of the company and bringing my experience of Regulatory Affairs to the work of the Advisory Board.”
About ELC Group:
ELC GROUP is a full-service global provider of regulatory affairs consultancy. ELC GROUP delivers a complete service solution covering all aspects of Regulatory Affairs for medicinal products, medical devices, cosmetics, food supplements and foods for special medicinal purposes. ELC GROUP also provides specialist REACH regulatory services to the Chemical industry and Corporate Language solutions for Automotive, Chemical and Defense industries.
ELC GROUP’s worldwide network of professionals spans all major Regulatory Affairs services across the key healthcare vertical markets of Pharmaceuticals, Biotech, Clinical, Consumer Healthcare, Medical Devices, Nutraceuticals and Veterinary. The team ranges from former FDA investigators to individuals with over 30 years of industry experience and broad capabilities, including in the areas of integrated advanced technologies, Regulatory Affairs consulting and commercialisation services.
ELC GROUP works with equal success in partnership with large multi-nationals, small enterprises and start-ups, biotechs, CROs and device manufacturers.
